Scott Barros

Scott Barros currently serves as SVP of Early Development at Aera Therapeutics since November 2024. Prior to this role, Scott held positions including Vice President of Drug Safety & In Vivo Sciences at Orna Therapeutics and VP of Toxicology & Pathology at ReNAgade Therapeutics. Scott's extensive experience in toxicology began at Sage Therapeutics as Senior Director and Head of Toxicology and included roles as Director of Nonclinical Development. Additional previous positions encompass Director of Investigative Toxicology at Alnylam Pharmaceuticals, Senior Scientist in Toxicology at Archemix Corp., and Principal Scientist in Toxicology at Novartis Pharmaceuticals, among others. Scott obtained a PhD in Toxicology from the University of North Carolina at Chapel Hill and a BS in Pharmacology & Toxicology from the University of Wisconsin-Madison.